生命科学资讯

Sarepta CEO Doug Ingram to retire after a decade of Duchenne breakthroughs and controversies

Analysts see potential in MDMA drug after AtaiBeckley reports improvements in anxiety trial

Boehringer pens $500M pact with British biotech for oral approach to autoimmune diseases

Bristol Myers' $800M ADC hits primary survival endpoints in phase 3 breast cancer trial

Quantum Surgical snaps up J&J's NeuWave Medical for its microwave ablation technology

Protagonist plans to pocket $400M from Takeda rather than split US rusfertide profits

Accent halts solid tumor trial over adverse events, pivots to other lead cancer program

Asahi Kasei scoops up Germany's Aicuris for $920M in R&D portfolio boost

ARPA-H designates up to $144M for anti-aging medical research

Worried Trump's MFN push will ‘destroy biotech innovation,’ midsize companies form coalition to fight back

Charles River sells manufacturing and discovery businesses to fulfill promised pivot

Novo Nordisk inks $2.1B pact with Langer startup to boost oral drug delivery prowess

After gene therapy exit, Pfizer locks in global license for Beam gene editing candidate

GSK pays $950M in cash for Canadian biotech and its Winrevair-like blood pressure drug

After 230% deal size explosion, China is no longer the 'bargain basement' for biopharma licensing: analyst

Werewolf weighs sale or merger as cash reserves whimper

Evinova reels in AI clinical development deals with Astellas and AstraZeneca

FDA freezes enrollment in MacroGenics cancer trial after patient death

Harbour ships CTLA-4 asset to form new biotech in $1.1B biobucks deal

GSK explores frontiers of siRNA with $1B deal for 2 drugs from Chinese biotech